Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026

Ref: Akums/Exchange/2026-27/64 November 05, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Transcript of the Earning/ Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026. Respected Sir/Ma’am, Pursuant to Regulation 30 read with Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the transcript of Earning/ Quarterly Conference Call held on Tuesday, November 03, 2026 at 12:00 P.M. (IST) on the un-audited financial results of Akums Drugs and Pharmaceuticals Limited (“the Company”) for the quarter and half year ended on September 30, 2026. The said transcript is also available on the Company’s website at https://www.akums.in/investors/investors-meet/ This is for your kind information and records. Thanking You Yours Faithfully For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl.: As above “Akums Drugs & Pharmaceuticals Limited Q2 FY27 Earning Conference Call” November 03, 2026 MANAGEMENT: MR. SANJEEV JAIN – MANAGING DIRECTOR – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. SANDEEP JAIN – MANAGING DIRECTOR – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. SUMEET SOOD – CHIEF FINANCIAL OFFICER – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. DAVINDER DOGRA – DEPUTY CHIEF FINANCIAL OFFICER – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. SAHIL MAHESHWARI – HEAD, STRATEGY – AKUMS DRUGS & PHARMACEUTICALS LIMITED MR. ANKIT JAIN – HEAD, INVESTOR RELATIONS – AKUMS DRUGS & PHARMACEUTICALS LIMITED Page 1 of 14 Akums Drugs & Pharmaceuticals Limited November 03, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Akums Drugs and Pharmaceuticals Limited Q2 FY27 Earning Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Ankit Jain from Akums. Thank you and over to you, sir. Ankit Jain: Good afternoon, everyone. Thank you, Swapnali, for introducing me. Welcome, everyone, to Akums Q2 FY27 Earnings Call. I am Ankit Jain and I Head Investor Relations at Akums Drugs and Pharmaceuticals Limited. On today's call, we are joined by Mr. Sanjeev Jain, Managing Director; Mr. Sandeep Jain, Managing Director; Mr. Sumeet Sood, CFO; Mr. Davinder Dogra, Deputy CFO; and Mr. Sahil Maheshwari, Head, Strategy. I will commence with our standard disclaimer that any discussion on today's call might include certain forward-looking statements, which are predictions or projections of future events. Our businesses face several risks and uncertainties that could cause our actual results to differ materially from what is expressed or implied in such statements. At Akums, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events or otherwise. I hope you've had the opportunity to go through our financial results and review our investor presentation that were shared yesterday. I would now like to hand over the call to our Managing Director, Mr. Sandeep Jain, to discuss our performance. Thank you. Sandeep Jain: Thank you, Ankit. Namaste, everyone, and thank you for joining us today for our Q2 FY27 and H1 FY27 earnings call. I am pleased to announce another quarter of strong performance by Akums, one of the world's leading pharmaceutical CDMO. The performance was driven by double-digit volume growth during the quarter. The revenue grew by more than 30% on year- on-year basis and EBITDA more than doubled during the corresponding period. Even sequentially, the quarter-on-quarter revenue growth stood at an impressive 15% and EBITDA increased by 11.5%. Led by strong order book and improved utilization of newer facilities, the CDMO business achieved a volume growth of more than 20% on September net MAT basis showcasing increasing penetration of our offering within the India pharma market. The improved performance is also an indicator of our resilience during times of global headwinds and geopolitical uncertainties. While the availability and the prices of input materials remain volatile, the demand outlook for CDMO remains strong. We today operate at healthy utilization levels of above 50%. During the quarter, we successfully integrated the 2 manufacturing plants acquired from Oriflame. With this, we have strengthened our beauty and personal care play as a fast-growing category in India. To cater to growing demand, we will operationalize a new facility at Baddi. Page 2 of 14 Akums Drugs & Pharmaceuticals Limited November 03, 2026 The plant will have oral solids in Phase 1 with an annual capacity of over 6 billion units, which will fully operationalize by Q1 FY28. With this plant, we will have 2 plants in Baddi in line with our stated objectives of geographical diversification. We remain steadfast on expanding as well as deepening our global footprints with special emphasis on regulated market. We have 2 products approved in Europe, 8 filed and over 30 in R&D, which we expect to commercialize over next 3-4 years. Our 2 facilities are EU-GMP certified and few more are in the pipeline. Our European CDMO project is progressing as per our stated plans with supplies commencing in FY28. Our JV with the Zambia government is also progressing smoothly with commercial supplies from the Indian plant scheduled during Q4 FY27 and considering the prolonged shipping time to Zambia, we expect to book revenues during Q1 FY28. The process for setting up the plant in the Zambia is well underway with technical discussions already complete. The plant is expected to become operational in 2029, expanding our manufacturing presence outside India. Our domestic branded formulations segment had a steady quarter with 8% year-on-year growth in revenue and improvement in profitability on a sequential basis. We expect the segment to deliver growth on par with IPM by FY28 as the current initiatives start bearing fruits. Our international branded formulations business saw growth accelerating both on year-on-year and quarter-on-quarter basis. It is expected to maintain this momentum going forward in the year and will be key engine to drive Akums' growth. API segment continued on its journey towards becoming EBITDA breakeven as our endeavor continued. The trade generics segment remained EBITDA positive during the quarter with the third straight quarter of achieving profitability. Sustainability is core to Akums in whatever we do. We are proud to announce that our company has an EcoVadis Bronze medal. We are on our journey to be amongst the top global companies focused on environment, labor rights, ethics and sustainability. We also won the Water Management Champion Award by CII for green practices. We also successfully transitioned to S/4HANA this quarter. This will provide real-time analytics across key business performances indicators. With number of initiatives underway, we remain confident in our ability to create long-term shareholder value and delivering positive results. I shall now request our CFO, Mr. Sumeet Sood, to take you through the detailed financials for the quarter. Over to you, Mr. Sumeet. Sumeet Sood: Thank you, sir. Thank you very much. Good afternoon, everyone. I'm pleased to present the financial highlights for the quarter 30th September 2026. Page 3 of 14 Akums Drugs & Pharmaceuticals [Showing first 8,000 characters — download PDF for full document]